VLA1553
Phase 3Withdrawn 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Chikungunya Virus Infection
Conditions
Chikungunya Virus Infection
Trial Timeline
Apr 10, 2024 → Aug 27, 2024
NCT ID
NCT06028841About VLA1553
VLA1553 is a phase 3 stage product being developed by Valneva SE for Chikungunya Virus Infection. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT06028841. Target conditions include Chikungunya Virus Infection.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06028841 | Phase 3 | Withdrawn |
| NCT04838444 | Phase 3 | Active |
| NCT03382964 | Phase 1 | Completed |
Competing Products
20 competing products in Chikungunya Virus Infection